MacroGenics Inc (MGNX) SVP Jon Marc Wigginton Sells 15,000 Shares

MacroGenics Inc (NASDAQ:MGNX) SVP Jon Marc Wigginton sold 15,000 shares of MacroGenics stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $20.00, for a total value of $300,000.00. Following the completion of the transaction, the senior vice president now owns 45,000 shares in the company, valued at approximately $900,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

MacroGenics Inc (NASDAQ:MGNX) traded up 3.23% during mid-day trading on Thursday, hitting $20.79. The company had a trading volume of 322,586 shares. MacroGenics Inc has a 1-year low of $16.28 and a 1-year high of $33.30. The stock’s market capitalization is $727.11 million. The stock has a 50 day moving average price of $18.74 and a 200-day moving average price of $21.91.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.14. The business had revenue of $5 million for the quarter, compared to analyst estimates of $10.65 million. MacroGenics had a negative return on equity of 16.99% and a negative net margin of 55.01%. The business’s revenue was down 37.5% compared to the same quarter last year. On average, analysts forecast that MacroGenics Inc will post ($3.73) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/markets/2065559/macrogenics-inc-mgnx-svp-jon-marc-wigginton-sells-15000-shares.html.

A number of institutional investors have recently bought and sold shares of MGNX. Interwest Venture Management Co. acquired a new position in MacroGenics during the fourth quarter worth $21,959,000. State Street Corp raised its position in MacroGenics by 1.0% in the fourth quarter. State Street Corp now owns 839,491 shares of the biopharmaceutical company’s stock worth $17,152,000 after buying an additional 8,661 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in MacroGenics during the fourth quarter worth $186,000. Baker BROS. Advisors LP acquired a new position in MacroGenics during the third quarter worth $10,878,000. Finally, BB Biotech AG raised its position in MacroGenics by 179.8% in the third quarter. BB Biotech AG now owns 1,455,000 shares of the biopharmaceutical company’s stock worth $43,519,000 after buying an additional 935,000 shares during the last quarter. Hedge funds and other institutional investors own 81.68% of the company’s stock.

MGNX has been the topic of several analyst reports. BTIG Research reiterated a “buy” rating and issued a $28.00 price objective (down previously from $35.00) on shares of MacroGenics in a report on Monday, March 6th. Cowen and Company reiterated a “buy” rating on shares of MacroGenics in a report on Wednesday, March 1st. Instinet initiated coverage on MacroGenics in a report on Wednesday, March 1st. They issued a “buy” rating and a $41.00 price objective on the stock. Nomura initiated coverage on MacroGenics in a report on Wednesday, March 1st. They issued a “buy” rating on the stock. Finally, Roth Capital set a $40.00 price objective on MacroGenics and gave the stock a “buy” rating in a report on Wednesday, March 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. MacroGenics presently has a consensus rating of “Buy” and a consensus price target of $36.30.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

5 Day Chart for NASDAQ:MGNX

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065559/macrogenics-inc-mgnx-svp-jon-marc-wigginton-sells-15000-shares.html

Receive News & Ratings for MacroGenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.